Three-dimensional (3D) bioprinting is bringing about a paradigm shift in personalised medicine in the 21st century. According to a report by Mordor Intelligence (1), the global 3D bioprinting market was valued at USD 724.17 million in 2020 and is expected to reach USD 2398.27 million by 2026, growing at a CAGR of 21.91% over the forecast period (2021-2026). It has been predicted that the Asia-Pacific region has the highest scope for growth due to present demands (2).
There’s presently an overwhelming demand for donated organs. However, it takes a long time to get an organ transplant through the donor list due to a shortage of adequate, compatible organ donors. There is also the matter of organ rejection and an extended course of immunosuppressants post transplantation (3). India has one of the lowest rates of organ donation in the world at 0.86 per million (4).
Traditional methods of tissue engineering haven't had much success in this aspect, both from a feasibility and economic point of view (5), bringing about a need for alternatives. Additionally, there are certain conditions, like spinal cord injuries, that currently have no known . . .